Latest On Provention Bio, Inc (PRVB):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-27 22:14 EST | News | Sanofi completes Provention Bio acquisition | N/A |  |
| 2023-04-26 21:10 EST | News | Provention Bio gains after HSR waiting period for Sanofi deal expired | N/A | |
| 2023-03-26 11:32 EST | News | Provention Bio: Sanofi Acquires Provention Bio With A 273% Premium | N/A | |
| 2023-03-15 15:43 EST | News | Provention Bio Q4 2022 Earnings Preview | N/A | |
| 2023-03-13 17:55 EST | News | Provention Bio stock rockets 260% on ~$2.9B acquisition by Sanofi | N/A | |
About Provention Bio, Inc (PRVB):
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company read more...has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
General
- Name Provention Bio, Inc
- Symbol PRVB
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 59
- Fiscal Year EndDecember
- IPO Date2018-07-24
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.proventionbio.com
Valuation
- Price/Book (Most Recent Quarter) 8.06
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.29
- Next Year EPS Estimate -$1.31
- Next Quarter EPS Estimate -$0.38
- Return on Assets -58%
- Return on Equity -102%
- Earnings Per Share -$0.94
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 826.41 million
- Analyst Target Price $29.43
- Book Value Per Share $1.97
Share Statistics
- Shares Outstanding 63.37 million
- Shares Float 45.82 million
- % Held by Insiders 1825%
- % Held by Institutions 42.82%
- Shares Short 2.8 million
- Shares Short Prior Month 2.86 million
- Short Ratio 3.31
- Short % of Float 5%
- Short % of Shares Outstanding 4%
Technicals
- Beta 3.36
- 52 Week High $19.19
- 52 Week Low $6.25
- 50 Day Moving Average 13.74
- 200 Day Moving Average 14.49
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Provention Bio, Inc (PRVB) Dividend Calendar:
Provention Bio, Inc (PRVB) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Provention Bio, Inc (PRVB) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Provention Bio, Inc (PRVB) Chart:
Provention Bio, Inc (PRVB) News:
Below you will find a list of latest news for Provention Bio, Inc (PRVB) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Provention Bio, Inc (PRVB) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest PRVB Trades:
Provention Bio, Inc (PRVB) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-10-30 | 8-K (Current report) | |
| 2020-09-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-24 | UPLOAD (SEC-generated letter) | |
| 2020-08-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-11 | 8-K (Current report) | |
| 2020-08-11 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 10-K/A (Annual report [Section 13 and 15(d), not S-K Item 405]) | |
| 2020-08-06 | 10-Q/A (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-06 | CORRESP (Correspondence) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
Provention Bio, Inc (PRVB) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Provention Bio, Inc (PRVB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1825%
Institutional Ownership: 4282%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-02 | Andrew T Drechsler | Chief Financial Officer | Buy | 2,000.00 | 11.72 | 23,440.00 | 20,000.00 | |
| 2020-09-02 | Eleanor Ramos | Chief Medical Officer | Buy | 299.00 | 12.06 | 3,605.94 | 64,799.00 | |
| 2020-08-21 | Francisco Leon | Chief Scientific Officer | Buy | 2,000.00 | 13.35 | 26,708.00 | 2,567,450.00 | |
| 2020-08-20 | Eleanor Ramos | Chief Medical Officer | Buy | 2,500.00 | 13.23 | 33,075.00 | 64,500.00 | |
| 2020-08-18 | Ashleigh Palmer | President and CEO | Buy | 500.00 | 12.69 | 6,345.00 | 2,566,300.00 | |
| 2020-08-17 | Ashleigh Palmer | President and CEO | Buy | 2,800.00 | 12.83 | 35,924.00 | 2,565,800.00 | |
| 2020-08-13 | Andrew T Drechsler | Chief Financial Officer | Buy | 1,750.00 | 13.01 | 22,767.50 | 18,000.00 | |
| 2020-06-24 | Francisco Leon | Chief Scientific Officer | Buy | 2,000.00 | 15.43 | 30,862.00 | 2,565,450.00 | |
| 2020-04-10 | Jeffrey Bluestone | Director | Buy | 32,246.00 | 2.36 | 76,100.56 | 39,571.00 | |
| 2020-03-19 | Francisco Leon | Chief Scientific Officer | Buy | 10,000.00 | 5.92 | 59,200.00 | 2,563,450.00 | |
| 2020-03-19 | Jason Hoitt | Chief Commercial Officer | Buy | 4,500.00 | 5.43 | 24,435.00 | 4,500.00 | |
| 2019-12-26 | Eleanor Ramos | CMO & COO | Buy | 2,000.00 | 14.34 | 28,680.00 | 62,000.00 | |
| 2019-12-20 | Ashleigh Palmer | President and CEO | Buy | 2,075.00 | 11.39 | 23,634.25 | 2,563,000.00 | |
| 2019-12-16 | Francisco Leon | Chief Scientific Officer | Buy | 2,000.00 | 11.92 | 23,840.00 | 2,553,450.00 | |
| 2019-09-30 | ANTHONY DIGIANDOMENICO | Director | Buy | 30,000.00 | 6.83 | 204,900.00 | 178,712.00 | |
| 2019-09-30 | Francisco Leon | Chief Scientific Officer | Buy | 1,450.00 | 7.67 | 11,121.50 | 2,551,450.00 | |
| 2019-09-26 | ANTHONY DIGIANDOMENICO | Director | Buy | 5,000.00 | 8.44 | 42,200.00 | 148,712.00 | |
| 2019-09-25 | ANTHONY DIGIANDOMENICO | Director | Buy | 5,000.00 | 8.39 | 41,950.00 | 143,712.00 | |
| 2019-09-24 | Ashleigh Palmer | President and CEO | Buy | 3,000.00 | 8.38 | 25,140.00 | 2,560,925.00 | |
| 2019-08-08 | ANTHONY DIGIANDOMENICO | Director | Buy | 10,000.00 | 9.09 | 90,900.00 | 138,712.00 | |